{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:16:58Z","timestamp":1780496218738,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.eplepsyres.2021.106561","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T17:08:37Z","timestamp":1610557717000},"page":"106561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures"],"prefix":"10.1016","volume":"171","author":[{"given":"John","family":"Hixson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-1487","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-9348","authenticated-orcid":false,"given":"Darshan","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Grinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2021.106561_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.eplepsyres.2018.08.011","article-title":"Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: a subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures","volume":"147","author":"Abou-Khalil","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2017.12.017","article-title":"Psychiatric and cognitive adverse events: a pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures","volume":"82","author":"Andermann","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0020","unstructured":"BIAL \u2013 Portela & Ca_ SA. Zebinix\u00ae (eslicarbazepine acetate). Summary of Product Characteristics https:\/\/www.medicines.org.uk\/emc\/product\/4460\/smpc 2020."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","article-title":"Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials","volume":"72","author":"Biton","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yebeh.2011.12.023","article-title":"Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures","volume":"23","author":"Borghs","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MLR.0000000000000912","article-title":"Choice defines QALYs: a US valuation of the EQ-5D-5L","volume":"56","author":"Craig","year":"2018","journal-title":"Med. Care"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","article-title":"Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory","volume":"39","author":"Cramer","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1037\/1040-3590.7.1.80","article-title":"Short form of the profile of mood states (POMS-SF): psychometric information","volume":"7","author":"Curran","year":"1995","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0050","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1474-4422(06)70415-X","article-title":"Rapid detection of major depression in epilepsy: a multicentre study","volume":"5","author":"Gilliam","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0060","series-title":"Lamictal\u00ae (lamotrigine) Prescribing Information","author":"GlaxoSmithKline","year":"2019"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0065","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ane.12574","article-title":"Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy","volume":"134","author":"Holtkamp","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0080","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00005053-198809000-00007","article-title":"Profiles of aggression among psychiatric patients. I. Nature and prevalence","volume":"176","author":"Kay","year":"1988","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0090","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0095","article-title":"Characteristics of adult patients with focal seizure receiving eslicarbazepine acetate therapy in routine clinical practice: evidence from a large US commercial claims database","author":"Mehta","year":"2018","journal-title":"Am. Epilepsy Soc."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.31887\/DCNS.2011.13.2\/hmoeller","article-title":"Effectiveness studies: advantages and disadvantages","volume":"13","author":"M\u00f6ller","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0105","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022780","article-title":"Mechanisms of action of antiseizure drugs and the ketogenic diet","volume":"6","author":"Rogawski","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/ane.13218","article-title":"Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate","volume":"141","author":"Rogin","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0125","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1212\/WNL.0000000000002497","article-title":"Conversion to eslicarbazepine acetate monotherapy: a pooled analysis of 2 phase III studies","volume":"86","author":"Sperling","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0130","series-title":"Aptiom\u00ae (eslicarbazepine acetate) Prescribing Information","author":"Sunovion Pharmaceuticals Inc","year":"2019"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0135","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/epi.13993","article-title":"Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study","volume":"59","author":"Trinka","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0140","series-title":"Keppra\u00ae (levetiracetam) Prescribing Information","author":"UCB Inc","year":"2019"},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.yebeh.2016.10.027","article-title":"Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: a pooled analysis of phase III clinical trials of eslicarbazepine acetate","volume":"68","author":"Velez","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2021.106561_bib0150","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/epi.16069","article-title":"Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy","volume":"60","author":"Wechsler","year":"2019","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121121000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:44:06Z","timestamp":1760276646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121121000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"alternative-id":["S0920121121000140"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106561","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106561"}}